Ocrelizumab approved for funding
Media Release – 7 October 2019 Hundreds with Multiple Sclerosis ‘Abandoned’ due to Pharmac Drug Access Criteria There’s concern that a Pharmac decision to fund the drug Ocrelizumab (Ocrevus) for certain patients with multiple sclerosis from December 1st will still see hundreds missing out due to the national drug-buying agency’s ‘inhumanely strict’ treatment access criteria. […]